introduction
Myocardial infarction (MI) is a major hazard disease to human health despite substantial advances in the control of risk factors and therapies with drugs and interventions including bypass surgery and stent placement. The MI caused heart failure (HF) could aggravate social burden and increase the mortality rate. The current therapeutic methods to treat HF just stay at delaying the disease progression without repair and regeneration. While heart transplantation is the only effective therapy for end-stage patients, limited supply of donor heart makes it impossible to meet the huge demand from the patients with HF. Therefore, how to solve the problem is an urgent issue.
Cell transplantation is one of the most promising treatments for the damaged myocardial tissue. The bone marrow-derived mesenchymal stem cells (MSCs) are the most used cells for the treatment of HF. Both animal and clinical studies had shown that MSCs are beneficial for cardiac repair and regeneration. However, the effect of cell treatment on HF is still limited, and how to improve the efficacy of cell therapy is the key issue.
In this review, we summarize the current literature on bone marrow-derived MSCs and their potential use to treat HF after MI. It cannot be denied that MSCs have been demonstrated beneficial competence in animal studies and clinical trials, which may open novel avenues for further clinical studies.
use of mesenchymal stromal cells for heart failure
MSCs were defined as a heterogeneous population of fibroblast-like multipotent cells which can differentiate into various mesodermal lineages such as adipocytes, chondrocytes, and osteocytes. They contribute to the regeneration of mesenchymal tissues such as bone, cartilage, tendon, adipose, and muscle. In addition, some studies showed that MSCs can also differentiate into ectoderm-type cells, [1, 2] for example, cardiomyocytes, [3] endothelial cells, or smooth muscle cells. [4, 5] MSCs were first isolated from bone marrow, but they can also be found in many other tissues, including but not limited to umbilical cord, placenta, muscle, and adipose tissue.
These different tissue-derived MSCs have similar biological characteristics. One of the MSC characteristics was easy to adhere to plastic. Moreover, they express surface markers CD73, CD90, and CD105, but not the hematopoietic markers CD45, CD34, CD14, CD79a, CD11b, and human leukocyte antigen (HLA)-DR. [7] Furthermore, many studies had shown that MSCs can escape immune surveillance in both human and animal models. [8, 9] It has been shown that MSCs express intermediate levels of HLA major histocompatibility Class I molecules and absent of Class II molecule on their surface. [10, 11] MSCs are the most used stem cells for the treatment of cardiac injury because they are easy to acquire from multiple tissues as mention above and easy to be modified by viral vectors. [12, 13] MSCs comprise 0.001%~0.1% of the total population of marrow nucleated cells and can be expanded in vitro extensively without loss of function or phenotype. [14, 15] Many cardiovascular regenerative studies from different groups demonstrated that MSCs can alleviate cardiac insult and promote recovery of heart function in animal model of acute MI (AMI). Because MSCs have immune privilege, allogeneic MSCs have also been used in the clinical study. [16] Some clinical studies using MSCs to treat patients with MI are listed in Table 1 .
Although cell therapy using MSCs is emerging as a promising approach for treating HF after MI, the issue of low efficacy still deserves for further study. It has been shown that, regardless of the administration method, only 1%-5% of delivered cells were retained within the target site after a few weeks.
[34-36] Nagaya et al. demonstrated that only 0.03% intravenously injected MSCs can be detected in the infarcted heart 1 month after injection.
[37] Similarly, another study found that only 1% MSCs survived after transplantation.
[38] A recent meta-analysis has shown that the efficacy of MSC transplantation was undesirable because of low survival and retention rate. [39] mechanisms of mesenchymal stem cell-mediated therapy
As one of the multipotent adult stem cells, the potential plasticity and self-renewal characteristics of MSCs make them a possible candidate for clinical tissue regeneration.
Most research data consistently demonstrate that MSC transplantation can improve cardiac function and retard ventricular remodeling in animals with MI. [40] [41] [42] Many clinical trials have also demonstrated that the MSCs-mediated therapy is helpful for patients who have suffered MI or HF. [18, 43, 44] Moreover, even though the evidence that MSCs can incorporate into vascular structure, numerous studies had shown that the number of transdifferentiated cells is minimal. While the beneficial effects were witnessed as a significant increase in capillary density and improved cardiac function after MSC transportation, the mechanisms behind these therapeutic effects have not been clearly defined. There exists an intense debate over differentiation versus cell fusion, which is much more complex than previously anticipated.
Recently, the paracrine effect of transplanted MSCs has been emphasized. An array of cytokines and growth factors are involved in paracrine effects of MSCs therapy. These factors are helpful in protecting cardiomyocytes from apoptosis and necrosis, promoting angiogenesis in infarcted myocardium, retarding matrix remodeling, and augmenting recruitment of circulating progenitor cells. Transplanted MSCs can upregulate multiple growth factors such as vascular endothelial growth factor (VEGF) which promotes angiogenesis, increases blood flow, and decreases apoptosis; the fibroblast growth factor (FGF) which acts as an angiogenic and antiapoptotic factor; the hepatocyte growth factor which has angiogenic, antiapoptotic, mitogenic, and antifibrotic effects; adrenomedullin which also has angiogenic, antiapoptotic, and antifibrotic effects; and the insulin-like growth factor-1 (IGF-1) which promotes cardiomyogenesis, antiapoptosis, positive inotropic effects, [40, [45] [46] [47] secreted frizzled-related protein (SFRP)-1 and SFRP-2, transforming growth factor β (TGF-β), [48] and so on. In addition, studies have shown that administration of conditioned medium from MSCs generated similar beneficial effects as the administration of the cells alone. [49] Nowadays, more and more evidences suggested that the extracellular vesicles secreted from MSCs may play a major role in the paracrine effect of MSCs. Exosome, a type of the extracellular vesicles, has been paid especial attention because it exerts principally the function as "cargo" of cellular material Table 1 : Clinical studies of mesenchymal stem cell-mediated therapy for heart failure after myocardial infarction
Trial name
Cell source
Route of delivery Effect on LV function
BOOST [17] BMSCs Intracoronary Positive REPAIR-AMI [18] BMSCs Intracoronary Positive REGENT [19] BMSCs Intracoronary No significant change MYSTAR [20] BMSCs It has been shown that compared with MSCs itself, exosomal content has 857 unique gene products [35] and >150 microRNAs. [50, 51] The recent study has demonstrated that MSCs-derived exosomes contain miR-22 which can silence methyl-CpG binding protein 2 (Mecp2) and reduce cardiomyocytes apoptosis under the ischemia condition. [52] Kang et al. extracted the exosome from CXCR4-overexpressing MSCs and showed that Exo CR4 can remarkably increase IGF-1 and pAkt levels and reduce active caspase 3 level in cardiomyocytes in vitro, and Exo CR4 can also improve angiogenesis and reduce infarction sizes. [53] Yu et al. isolated and purified exosome from GATA-4-overexpressing MSCs and showed that Exo GATA-4 contains antiapoptotic miRs in a high expression level, especially the miR-19a which play a major role in activating cardiomyocytes' survival signaling pathway. [54] actiVation of mesenchymal stem cells to improVe their efficacy of therapy MSCs are the ideal progenitor cells for MI. However, their retention rate is low. After cell transportation, the retained MSCs in the infarcted areas are gradually decreased day by day, due to the inflamed, hypoxic, ischemic environment which is harsh for MSCs to survive. It is reported that the survival rate is lower than 0.44% at day 4 after cell transplantation. [55, 56] Furthermore, the patients receiving the autologous MSCs are usually old and with diseases. The activities of MSCs from the aged person with diseases are usually impaired. Hence, how to enhance the activity of MSCs and to improve their retention or survival rate is a challenge in the field of cell therapy.
Nowadays, multiple methods have been explored to improve the efficiency of MSCs, which includes genetic modification, preconditioning, and combining with tissue engineering materials, which are detailed below.
Genetic modification
MSCs are also ideal target for genetic modification because they can maintain stable expression of exogenous genes. Different kinds of exogenous genes have been used to modify the property of MSCs so that improved efficiency of treatment will be achieved when the modified MSCs are transplanted.
It had been showed that physical senescence has an adverse influence on the therapeutic effects of MSCs. Data from our group have shown that overexpressing silent mating type information regulation 2 homolog 1 (SIRT1) can ameliorate senescent phenotype and the function of aged MSCs and thus enhance the efficacy of aged MSCs-based therapy for MI. We also showed that Bcl-2/Bax ratio and the expression of proangiogenic factors such as angiopoietin 1 and basic FGF (bFGF), were increased, and the expression of antiangiogenic factor, thrombospondin-1, was reduced in the genetically modified aged MSCs. [57] Some antiapoptosis factors had been studied in the genetically modified MSCs. For example, AKT which is a key kinase involved in cell apoptosis and cell proliferation possesses a possible myocardial protective function. [58] [59] [60] [61] Mangi et al. suggested that AKT-upregulated MSCs had a better survival rate which is in parallel with lessened collagen deposition and inflammatory response and alleviated infarction region/ventricular remodeling. [60] Recently, Huang et al. demonstrated that hypoxia and Akt-induced stem cell factor secreted by Akt-transduced MSCs have a cytoprotective effect on ischemia-induced cardiomyocyte death. [62] Heme oxygenase-1 (HO-1) is a cytoprotective protein whose expression is consistently associated with therapeutic benefits in a number of pathological conditions such as inflammation. [63] Meanwhile, the HO-1 induction has been further demonstrated to play a critical role in anti-inflammatory effect and attenuating myocardial ischemia-reperfusion injury. [64] Tang et al. showed that the survival rate of HO-1-transfected MSCs was five-fold greater than the control group in a mouse MI model. [65] Meanwhile, Jiang et al. suggested that HO-1 modified MSCs increased density of both capillary and arteriolar, as well as the cardiac function in postinfarct swine hearts. [66] For a long time, most of the studies used virus as the vector to deliver the target gene. They include lentivirus, adenovirus, and retrovirus. Nowadays, nonviral delivery systems, such as liposomes, polymers, electroporation, and nuclei transfection, [67] have also been applied. Continuous advances of these techniques will further improve outcome of therapy with the genetic engineered MSCs.
Preconditioning
Preconditioning MSCs either physically or chemically can induce certain cellular pathways which improve engraftment and survival of transplanted cells. It had been verified that precondition can achieve a similar effect as the use of viral transfection. Treatment of MSCs under hypoxic condition, cultured with drugs, and heat shock are the commonly used approaches. [68, 69] Hypoxic preconditioning (HPC) involves pre-exposing stem cells to severe hypoxia before cell transplantation. HPC of several cell types including MSCs has been shown to augment cell survival, recruitment, differentiation, and angiogenesis. [70, 71] Hu et al. had reported that HPC of autologous MSCs significantly improved homing, engraftment, and therapy of rodent hearts after MI. [72, 73] Chacko et al. suggested that MSCs had a state of optimal expression of prosurvival, proangiogenic, and functional proteins that may increase the survival and engraftment in the infarct heart after 24 h HPC. [74] Current studies suggested that HPC upregulate the expression of hypoxia-inducible factor-1 through the PI3K/AKT pathway to improve the antiapoptotic capability of MSCs. [55] In addition, Hu et al. demonstrated that HPC effect is mediated through a regulatory role of Kv2.1 on Focal adhesion kinase phosphorylation/activation. [72] Furthermore, Hu et al. also showed that leptin signaling is an early and essential step for the enhanced survival, chemotaxis, and therapeutic properties of MSCs conferred by preculture under hypoxia. Leptin may play a physiological role in priming MSCs resident in the bone marrow endosteum for optimal response to systemic signaling molecules and subsequent tissue repair. [75] HPC is a simple method and can produce many biological effects. Therefore, it is currently a common preconditioning method used before MSCs are transplanted into the infarction region. Our laboratory has also demonstrated the beneficial effect of HPC MSCs in a large animal model of MI with 50 monkeys (manuscript under submission). This method has also been successful applied to a clinical study. [76] However, the optimal oxygen levels and cell culture time need to be further investigation.
Renin-angiotensin system was involved in cardiac remodeling after MI. [77] Xu et al. demonstrated that preconditioning of bone marrow-derived mononuclear cells through AT2R stimulation exerts protective effect against MI. [78] 
Combined with engineering materials
Combining engineering materials with MSCs for transplantation can provide MSCs with a scaffold for attachment and growth. Meanwhile, design of engineered tissues from cell proliferation and differentiation is one of the key objectives of tissue engineering. [79] Using this approach, cells can be better retained at the infarcted sites so that survived cells can sustainably release multiple cytokines/microRNA to ameliorate the ambient environment of the infarction region and stimulate survival/differentiation of the transplanted cells. Currently, there are two primary kinds of cardiac tissue engineering materials: cardiac patch which is seeded with MSCs and can be placed on the heart surface during surgery, and gel scaffolds which encapsulate MSCs and can be directly injected into the infarction region.
Simpson et al. seeded MSCs onto a cardiac patch made of collagen protein and found that this patch can improve MSC survival and therapeutic effect which is in accord with ameliorated cardiac function, but they also found that transplanted MSCs were not detectable at 4 weeks after patch application, implying that heart function improvement did not need long-term cell engraftment. [80] Xiang et al. investigated the type I collagen-glycosaminoglycan scaffold for the transportation of adult bone marrow-derived MSCs into the infarcted region in the rat heart. A substantial amount of neovascularization was seen in the infarcted region in the implant groups and in the scaffolds themselves. [81] Another studies had used the gel-like alginates combined with MSCs for improving cell therapy outcome. Panda et al. showed that 2% alginates have a better result in MSCs retention and survival in pig MI model. [82] Similarly, Ceccaldi et al. created a three-dimensional scaffold with mixed alginate and chitosan; this MSCs seeded scaffold can significantly increase in the ejection fraction, improve neovascularization, attenuate fibrosis as well as reduce left ventricular dilatation. [83] Recombinant cytokines and beneficial proteins are under broad preclinical and clinical investigation to promote angiogenesis, but they are lack of long-term stability and excessive cost due to useless delivery approach. Recently, some studies have prepared tissue engineering materials with different kinds of cytokines. Davis et al. coupled IGF-1 to the cardiac patch; this sustaining released IGF-1 activated Akt, decreased activation of caspase-3, and increased expression of cardiac troponin I in cardiomyocytes. [84] Glycine-histidine-lysine (GHK) is a peptide fragment of osteonectin, a matricellular protein with reported proangiogenic potential. Jose et al. covalently coupled GHK to alginate and detected that MSCs react to GHK-modified gels by secreting increased concentrations of VEGF and bFGF.
summary
HF after MI represents a worldwide public health issue, which affects various organs and tissues and is associated with a significant morbidity and mortality. In the absence of specific target-oriented therapy, the treatment of patients presenting with HF mostly relies on supportive maneuvers. MSC has demonstrated immunomodulatory, anti-inflammatory, and tissue repair properties in many animal studies and in ongoing clinical trials. Their administration at the time of MI and/or at later times may attenuate its severity and accelerate the regeneration process. Genetic modification, precondition, and tissue engineering in combination with biomaterials have been applied to improve the efficacy of MSC transplantation. The combined application of a variety of these methods could further improve the MSCs therapeutic effect. In the future, this approach will contribute to improve and expand current applications of stem cell treatments.
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